SecurityCCM / Concord Medical Services Holdings Ltd. (206277105)
Form 6-K Count50
Form 20-F Count7
Form SC 13D/A Count6
Form SC 13G/A Count5

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Concord Medical Services Holdings Ltd.


DateFormTitle
2018-04-30 20-F CCM / Concord Medical Services Holdings Ltd. 20-F
2018-04-04 6-K CCM / Concord Medical Services Holdings Ltd. FORM 6-K (Current Report of Foreign Issuer)
2018-02-13 SC 13G/A CCM / Concord Medical Services Holdings Ltd. / Carlyle Group L.P. - SC 13G/A (Passive Investment)
2018-02-13 SC 13G/A CCM / Concord Medical Services Holdings Ltd. / Carlyle Group L.P. - SC 13G/A (Passive Investment)
2018-01-16 S-8 CCM / Concord Medical Services Holdings Ltd. FORM S-8
2017-12-21 6-K CCM / Concord Medical Services Holdings Ltd. 6-K (Current Report of Foreign Issuer)
2017-11-28 6-K CCM / Concord Medical Services Holdings Ltd. FORM 6-K (Current Report of Foreign Issuer)
2017-11-14 6-K CCM / Concord Medical Services Holdings Ltd. FORM 6-K (Current Report of Foreign Issuer)
2017-11-14 SC 13D/A CCM / Concord Medical Services Holdings Ltd. / Cheng Zheng - SCHEDULE 13D/A (Activist Investment)
2017-11-14 SC 13D/A CCM / Concord Medical Services Holdings Ltd. / Cheng Zheng - SCHEDULE 13D/A (Activist Investment)
2017-11-13 SC 13D CCM / Concord Medical Services Holdings Ltd. / Fosun International Ltd - SCHEDULE 13D (Activist Investment)
2017-11-13 SC 13D CCM / Concord Medical Services Holdings Ltd. / Fosun International Ltd - SCHEDULE 13D (Activist Investment)
2017-09-18 6-K Concord Medical Services Holdings 6-K (Current Report of Foreign Issuer)
2017-08-31 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-07-26 6-K Concord Medical Services Holdings 6-K (Current Report of Foreign Issuer)
2017-05-23 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-05-23 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-05-01 20-F Concord Medical Services Holdings 20-F
2017-02-09 SC 13E3 Concord Medical Services Holdings SC 13E3
2017-02-09 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-02-09 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2016-11-22 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2016-11-22 SC 13D/A Concord Medical Services Holdings SCHEDULE 13D/A (Activist Acquisition of More Than 5% of Shares)
2016-08-25 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2016-07-11 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2016-07-11 SC 13D/A Concord Medical Services Holdings SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2016-07-11 SC 13D/A Concord Medical Services Holdings SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2016-05-24 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2016-04-28 20-F Concord Medical Services Holdings FORM 20-F
2016-03-29 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2016-02-10 LETTER Concord Medical Services Holdings Form LETTER
2016-02-10 LETTER Concord Medical Services Holdings Form LETTER
2016-02-10 CORRESP Concord Medical Services Holdings Form CORRESP
2016-01-28 6-K Concord Medical Services Holdings Form 6-K (Current Report of Foreign Issuer)
2017-06-16 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-06-16 LETTER Concord Medical Services Holdings ER
2017-06-16 CORRESP Concord Medical Services Holdings ESP
2017-06-17 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2015-12-16 6-K Concord Medical Services Holdings Form 6-K (Current Report of Foreign Issuer)
2017-06-17 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2015-12-12 6-K Concord Medical Services Holdings Form 6-K (Current Report of Foreign Issuer)
2017-06-17 LETTER Concord Medical Services Holdings ER
2017-06-17 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2015-11-19 6-K Concord Medical Services Holdings Form 6-K (Current Report of Foreign Issuer)
2015-10-19 F-6 POS Concord Medical Services Holdings Form F-6 POS
2017-06-18 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-06-19 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-06-19 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-06-19 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)
2017-06-21 6-K Concord Medical Services Holdings FORM 6-K (Current Report of Foreign Issuer)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

15h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 206277105